Drug Target Review – Issue #2 2017
Posted: 2 June 2017 | Drug Target Review | No comments yet
Included in this issue: Technology convergence improves testing; Screening; Stem Cells; Targets; Mass Spectrometry; and Therapeutics in Alzheimer’s disease…
- Foreword: Technology convergence improves testing models
Anton Simeonov, Scientific Director of the Division of Pre-Clinical Innovation (DPR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health - In-Depth Focus: Screening
- Genomics: Review: biomarkers towards personalised therapy in cancer
Mahvash Tavassoli and Katheryn Begg, King’s College London - In-Depth Focus: Stem Cells
- Mass Spectrometry: Using native mass spectrometry to inform drug discovery
Idlir Liko, OMass Technologies and University of Oxford; Timothy M Allison, OMass Technologies and University of Oxford; Hsin-Yung Yen, OMass Technologies and University of Oxford; Jonathan S.T. Hopper, OMass Technologies; Carol V. Robinson, OMass Technologies and University of Oxford - In-Depth Focus: Targets
- Research area: CNS: Insights from discovery through clinical efficacy to support a new class of therapeutics in Alzheimer’s disease
Petr Kocis, John A Hey, Susan Abushakra, Aidan Power, and Martin Tolar, Alzheon
The digital version of Issue #2 2017 is restricted - login or subscribe free to access
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Biomarkers, Drug Development, Drug Discovery, Drug Targets, Mass Spectrometry, Oncology, Screening, Stem Cells, Therapeutics